Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck
A phase 2 trial of Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by NATCO Pharma Ltd., now recruiting.
Overview
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy is a phase 2 interventional study registered as NCT05283226 by NATCO Pharma Ltd., with 21 participants planned, started 2022-09-30 and due to reach its primary completion in 2026-12-30. Interventions recorded: NRC-2694-A, Paclitaxel. Conditions listed: Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialA Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialA Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- PersonAkhil Kapoor
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialAK129 Combination Therapy for Advanced Solid Tumors
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialA Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.